Y2641
Y2641, a etrahydro-β-carboline derivative, is an orally active dual RANKL/TNF-α inhibitor with Kd values of 3.984 μM and 18.59 μM for RANKL and TNF-α, respectively. Y2641 inhibits RANKL-induced osteoclastogenic and has anti-inflammatory and cartilage destruction. Y2641 can be used for study of osteoarthritis[1].
Product Specifications
UNSPSC
12352005
Target
RANKL/RANK ; TNF Receptor
Related Pathways
Apoptosis; NF-κB
Field of Research
Inflammation/Immunology
Smiles
O=C([C@@H]1CC(C2=CC=CC=C2N3)=C3C4(CN(C4)C5=CC=CC=C5)N1)NC6=C(C=CC=C6C)C
Molecular Formula
C28H28N4O
Molecular Weight
436.55
References & Citations
[1]Shao Z, et al. Identification of a RANKL/TNF-α Dual-Inhibitor as a Potential Disease-Modifying Agent for the Treatment of Knee Osteoarthritis. J Med Chem. 2025 May 22;68 (10) :10216-10237.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400026-500 1x 500 µL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040102-100 1x 100 µL
Golgi Complex (371-4), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401448-100 1x 100 µL
Factor XIIIa (Coagulation Factor XIIIA Chain) (F13A1/1448), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details